These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10441401)

  • 1. Validation of assays for use with combination vaccines.
    Klein J; Capen R; Mancinelli R; Robinett R; Pietrobon PJ; Quinn J; Schofield T
    Biologicals; 1999 Mar; 27(1):35-41. PubMed ID: 10441401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency tests of combination vaccines.
    Taffs RE
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S362-6. PubMed ID: 11709774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical approach to optimization and validation of a HPLC assay for analysis of polyribosyl-ribitol phosphate in complex combination vaccines.
    Belfast M; Lu R; Capen R; Zhong J; Nguyen MA; Gimenez J; Sitrin R; Mancinelli R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 832(2):208-15. PubMed ID: 16473567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Setting specifications for potency assays--basic principles.
    Mire-Sluis AR
    Dev Biol (Basel); 2002; 107():107-15. PubMed ID: 12079184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioassays for the characterisation and control of therapeutic cytokines; determination of potency.
    Thorpe R; Wadhwa M; Page C; Mire-Sluis A
    Dev Biol Stand; 1999; 97():61-71. PubMed ID: 10463531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro potency assay for hepatitis A vaccines: development of a unique economical test.
    Poirier B; Morgeaux S; Variot P; Fuchs F
    Biologicals; 2000 Dec; 28(4):247-56. PubMed ID: 11237361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of assay validation in specification development.
    Baffi RA
    Dev Biol Stand; 1997; 91():105-13. PubMed ID: 9413687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacturing issues with combining different antigens: a regulatory perspective.
    Falk LA; Arciniega J; McVittie L
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S351-5. PubMed ID: 11709772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Vitotox and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development.
    Westerink WM; Stevenson JC; Lauwers A; Griffioen G; Horbach GJ; Schoonen WG
    Mutat Res; 2009 May; 676(1-2):113-30. PubMed ID: 19393335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and use of a novel in vitro assay for testing of diphtheria toxoid in combination vaccines.
    Coombes L; Stickings P; Tierney R; Rigsby P; Sesardic D
    J Immunol Methods; 2009 Oct; 350(1-2):142-9. PubMed ID: 19761770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.
    Sweep FC; Fritsche HA; Gion M; Klee GG; Schmitt M;
    Int J Oncol; 2003 Dec; 23(6):1715-26. PubMed ID: 14612946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ensuring quality of in vitro alternative test methods: Current practice.
    Rispin A; Stitzel K; Harbell J; Klausner M
    Regul Toxicol Pharmacol; 2006 Jul; 45(2):97-103. PubMed ID: 16644076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation in pharmaceutical analysis. Part II: Central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data.
    Ermer J; Ploss HJ
    J Pharm Biomed Anal; 2005 Apr; 37(5):859-70. PubMed ID: 15862659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardization of steroid hormone assays: why, how, and when?
    Stanczyk FZ; Lee JS; Santen RJ
    Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1713-9. PubMed ID: 17855686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of bioassays for quality control.
    Lansky D
    Dev Biol Stand; 1999; 97():157-68. PubMed ID: 10463541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring.
    Hayashi M; MacGregor JT; Gatehouse DG; Adler ID; Blakey DH; Dertinger SD; Krishna G; Morita T; Russo A; Sutou S
    Environ Mol Mutagen; 2000; 35(3):234-52. PubMed ID: 10737958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of analytical quality specifications for biomarker assays currently used in acute cardiac care.
    Panteghini M
    Acute Card Care; 2006; 8(3):133-8. PubMed ID: 17012126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality assurance/quality control of foot and mouth disease solid phase competition enzyme-linked immunosorbent assay--Part II. Quality control: comparison of two charting methods to monitor assay performance.
    Goris N; De Clercq K
    Rev Sci Tech; 2005 Dec; 24(3):1005-16. PubMed ID: 16642771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.